BioInvent presented the complete Part B cohort of BI-1808 plus pembrolizumab in platinum-resistant ovarian cancer at ESMO 2026. With 34 evaluable patients (25 at ASCO), the objective response remained at 24%. Median PFS was 4.1 months under RECIST and 10.3 months under iRECIST.
LÄS MER
